Teladoc Health (TDOC)
Market Price (12/5/2025): $7.75 | Market Cap: $1.4 BilSector: Health Care | Industry: Health Care Technology
Teladoc Health (TDOC)
Market Price (12/5/2025): $7.75Market Cap: $1.4 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% | Weak multi-year price returns2Y Excs Rtn is -107%, 3Y Excs Rtn is -145% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1% |
| Attractive yieldFCF Yield is 10% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Attractive yieldFCF Yield is 10% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -107%, 3Y Excs Rtn is -145% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -7.1% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -2.4%, Rev Chg QQuarterly Revenue Change % is -2.2% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
Valuation, Metrics & Events
TDOC Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
Teladoc Health (TDOC) experienced movement in its stock, influenced by various corporate developments and market conditions. While the precise 0.6% movement for a future period cannot be explained, the following key points highlight factors that have recently impacted the stock based on available information up to early December 2024, or for future guidance given in late 2024 for 2025.
1. Mixed Q3 2024 Financial Results: Teladoc Health reported mixed financial results for the third quarter of 2024. The company's consolidated revenue decreased by 3% year-over-year to $640.5 million. However, the Integrated Care segment saw a 2% increase in revenue, while the BetterHelp segment experienced a 10% decline. The net loss per share improved to $0.19, down from a $0.35 loss in Q3 2023, and free cash flow increased by 16% year-over-year to $79 million. This mix of declines in overall revenue and BetterHelp, coupled with growth in Integrated Care and improved net loss, likely contributed to fluctuations in investor sentiment.
2. BetterHelp Segment Underperformance: The BetterHelp segment continued to be a drag on Teladoc's overall performance, with a 10% drop in revenue in Q3 2024 and a significant non-cash goodwill impairment charge of $790 million recorded in the first nine months of 2024, attributed to changes in future cash flow estimates related to this segment. The ongoing challenges and uncertainties surrounding BetterHelp's revenue and future guidance have likely created downward pressure on the stock.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TDOC Return | 139% | -54% | -74% | -9% | -58% | -14% | -91% |
| Peers Return | 74% | 14% | -32% | 8% | -16% | 70% | 109% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 112% |
Monthly Win Rates [3] | |||||||
| TDOC Win Rate | 83% | 25% | 25% | 50% | 25% | 40% | |
| Peers Win Rate | 28% | 32% | 47% | 55% | 38% | 48% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| TDOC Max Drawdown | -1% | -56% | -75% | -34% | -68% | -28% | |
| Peers Max Drawdown | -14% | -6% | -52% | -19% | -39% | -21% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: GH, PRVA, LFST, FLGT, INNV. See TDOC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/4/2025 (YTD)
How Low Can It Go
| Event | TDOC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -94.7% | -25.4% |
| % Gain to Breakeven | 1791.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -30.9% | -33.9% |
| % Gain to Breakeven | 44.6% | 51.3% |
| Time to Breakeven | 73 days | 148 days |
| 2018 Correction | ||
| % Loss | -50.3% | -19.8% |
| % Gain to Breakeven | 101.4% | 24.7% |
| Time to Breakeven | 378 days | 120 days |
Compare to GH, PRVA, LFST, FLGT, INNV
In The Past
Teladoc Health's stock fell -94.7% during the 2022 Inflation Shock from a high on 2/8/2021. A -94.7% loss requires a 1791.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | Date | |
|---|---|---|---|
| DASHBOARDS | |||
| Would You Still Hold Teladoc Health Stock If It Fell Another 30%? | Return | ||
| Teladoc Health (TDOC) Revenue Comparison | Financials | ||
| Teladoc Health (TDOC) Operating Income Comparison | Financials | ||
| Teladoc Health (TDOC) Net Income Comparison | Financials | ||
| Teladoc Health (TDOC) Debt Comparison | Financials | ||
| Teladoc Health (TDOC) EBITDA Comparison | Financials | ||
| Teladoc Health (TDOC) Operating Cash Flow Comparison | Financials | ||
| Teladoc Health (TDOC) Tax Expense Comparison | Financials | ||
| TDOC Dip Buy Analysis | |||
| Teladoc Health vs. Azenta: Both Seem Similar Bets | Peer Comparison | ||
| ARTICLES | |||
| What’s Next For Teladoc Stock After An 89% Fall In Three Years? | July 7th, 2023 | ||
| Teladoc, CRISPR: Finally Time To Buy Beaten Down Healthcare Names? | June 8th, 2022 | ||
| Down 20% In A Month, Is Teladoc Stock A Buy? | January 25th, 2022 | ||
| Here’s Why Teladoc Stock Looks Attractive At $140 | May 17th, 2021 |
Trade Ideas
Select past ideas related to TDOC. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
| 04302024 | TDOC | Teladoc Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -30.0% | -43.6% | -48.9% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 10.0% | 10.0% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.7% | -7.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 6.9% | 6.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 11.5% | 11.5% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 8.9% | 8.9% | -5.1% |
| 04302024 | TDOC | Teladoc Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | -30.0% | -43.6% | -48.9% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Teladoc Health
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 15.89 |
| Mkt Cap | 1.9 |
| Rev LTM | 1,135 |
| Op Inc LTM | -37 |
| FCF LTM | 73 |
| FCF 3Y Avg | 15 |
| CFO LTM | 78 |
| CFO 3Y Avg | 45 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 13.5% |
| Rev Chg 3Y Avg | 12.9% |
| Rev Chg Q | 16.8% |
| QoQ Delta Rev Chg LTM | 4.0% |
| Op Mgn LTM | -3.7% |
| Op Mgn 3Y Avg | -8.0% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 5.2% |
| CFO/Rev 3Y Avg | 5.1% |
| FCF/Rev LTM | 4.7% |
| FCF/Rev 3Y Avg | 0.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.9 |
| P/S | 1.5 |
| P/EBIT | -9.1 |
| P/E | -17.9 |
| P/CFO | 14.9 |
| Total Yield | -3.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.5% |
| D/E | 0.2 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 8.5% |
| 3M Rtn | 23.4% |
| 6M Rtn | 21.0% |
| 12M Rtn | 8.2% |
| 3Y Rtn | -9.6% |
| 1M Excs Rtn | 7.2% |
| 3M Excs Rtn | 18.8% |
| 6M Excs Rtn | 5.5% |
| 12M Excs Rtn | -7.1% |
| 3Y Excs Rtn | -78.3% |
Comparison Analyses
Segment Financials
Revenue by Segment
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integrated Care | 1,469 | 1,374 | 1,301 | ||
| BetterHelp | 1,134 | 1,020 | 721 | ||
| Other | 0 | 13 | 11 | 25 | |
| Access Fees Revenue | 847 | 463 | |||
| Visit Fee Revenue | 222 | 90 | |||
| Total | 2,602 | 2,407 | 2,033 | 1,094 | 553 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integrated Care | 192 | 135 | |||
| BetterHelp | 136 | 114 | |||
| Goodwill impairment | 0 | -13,403 | |||
| Other | 0 | -3 | |||
| Depreciation of property and equipment | -11 | -11 | |||
| Restructuring costs | -17 | -7 | |||
| Acquisition, integration, and transformation costs | -21 | -16 | |||
| Stock-based compensation | -202 | -218 | |||
| Amortization of intangible assets | -326 | -245 | |||
| Total | -249 | -13,653 |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10302025 | 10-Q 9/30/2025 |
| 6302025 | 7302025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 2272025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 8012024 | 10-Q 6/30/2024 |
| 3312024 | 4262024 | 10-Q 3/31/2024 |
| 12312023 | 2232024 | 10-K 12/31/2023 |
| 9302023 | 10272023 | 10-Q 9/30/2023 |
| 6302023 | 7282023 | 10-Q 6/30/2023 |
| 3312023 | 5022023 | 10-Q 3/31/2023 |
| 12312022 | 3012023 | 10-K 12/31/2022 |
| 9302022 | 11022022 | 10-Q 9/30/2022 |
| 6302022 | 8032022 | 10-Q 6/30/2022 |
| 3312022 | 5022022 | 10-Q 3/31/2022 |
| 12312021 | 2282022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | Paulus Kenneth H | 11172025 | Buy | 6.94 | 10,000 | 69,400 | 69,400 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |